tetrabenazine

Ligand id: 4834

Name: tetrabenazine

Abbreviated name: TBZ

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 38.77
Molecular weight 317.2
XLogP 2.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
Approved drug? Yes (FDA (2008))
IUPAC Name
9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-one
International Nonproprietary Names
INN number INN
1056 tetrabenazine
Synonyms
Nitoman® | Revocon® | Ro-19569
Database Links
CAS Registry No. 58-46-8 (source: Scifinder)
ChEMBL Ligand CHEMBL117785
DrugBank Ligand DB04844
PubChem CID 6018
Search Google for chemical match using the InChIKey MKJIEFSOBYUXJB-UHFFFAOYSA-N
Search Google for chemicals with the same backbone MKJIEFSOBYUXJB
Search PubMed clinical trials tetrabenazine
Search PubMed titles tetrabenazine
Search PubMed titles/abstracts tetrabenazine
Search UniChem for chemical match using the InChIKey MKJIEFSOBYUXJB-UHFFFAOYSA-N
Search UniChem for chemicals with the same backbone MKJIEFSOBYUXJB
Wikipedia Tetrabenazine
Comments
Tetrabenazine is an inhibitor of the vesicular monoamine transporter type 2 (VMAT2; SLC18A2). Tetrabenazine was the first dopamine-depleting drug approved in the US for the treatment of Huntington's disease. The potential for using dopamine-depleters to manage hyperkinetic movement disorders is reviewed in [2]. Since the approval of tetrabenazine, the deuterated analogue deutetrabenazine has been a granted marketing authorisation by the FDA (April 2107), and valbenazine is in clinical trial for tardive dyskinesia and Tourette syndrome